ARTICLE | Clinical News
Study shows no safety concerns for Gaucher's switch
November 2, 2010 10:55 PM UTC
Protalix Biotherapeutics Inc. (NYSE-A:PLX; Tel Aviv:PLX) said preliminary data from the first 15 Gaucher's disease patients in a Phase III trial showed that switching from Cerezyme imiglucerase to an ...